Avantax Advisory Services’s Filana Therapeutics FLNA Stock Holding History

Avantax Advisory Services’s Portfolio FLNA Stock Details FLNA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-3,513	Closed	-$218K	–	1275
2021 Q3	$218K	Buy	3,513 +838	+31%	+$69.9K	﹤0.01%	1070
2021 Q2	$229K	Buy	+2,675	New	+$143K	﹤0.01%	1019
2020 Q4	–	Sell	-15,750	Closed	-$183K	–	1286
2020 Q3	$183K	Buy	+15,750	New	+$71K	﹤0.01%	1241

Other funds holding FLNA

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Norges Bank Oslo, Norway $935B AUM

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Avantax Advisory Services's FLNA Position: Q4 2021 in Review

Avantax Advisory Services sold out of Filana Therapeutics (FLNA) in Q4 2021, closing a stake of 3,513 shares — an estimated $218K sold.

Avantax Advisory Services first reported a position in FLNA in Q3 2020 and held it in 3 quarters. The position peaked at $229K in Q2 2021. 171 funds tracked by Wall St. Rank hold FLNA as of Q4 2021.

Avantax Advisory Services reported no remaining Filana Therapeutics position as of Q4 2021 after selling out during the quarter.
Avantax Advisory Services sold 3,513 Filana Therapeutics shares in Q4 2021, an estimated $218K.
Avantax Advisory Services first reported a position in Filana Therapeutics in Q3 2020 and held it in 3 quarters.
Avantax Advisory Services's Filana Therapeutics position peaked at $229K in Q2 2021.
171 funds tracked by Wall St. Rank held Filana Therapeutics as of Q4 2021.

Based on Avantax Advisory Services's 13F filing for Q4 2021, filed 24 Jan 2022.